A review of nonsurgical facial rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1% in periorbital revitalization
Journal of Cosmetic Dermatology · 2024
DOI: 10.1111/jocd.16018 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von David J Goldberg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Schweiger Dermatology Group, Hackensack, New Jersey, USA. Hauptthemen laut MEDLINE: Cosmetic Techniques, Dermal Fillers, Botulinum Toxins, Type A, Blepharoptosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RVL Pharmaceuticals.
Abstract (Originalsprache)
Background
The demand for nonsurgical facial rejuvenation options is growing, yet the periorbital region remains an area of relative unmet need. This review explores nonsurgical options for facial rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1%, in treating age‐related blepharoptosis as part of periorbital rejuvenation.
Methods
Advisors experienced in facial rejuvenation met to discuss existing literature on the upper face and periorbital rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1%, in treating facial aging.
Results
An array of nonsurgical options exist to address the signs of aging, including minimally invasive treatments, such as botulinum toxin injections and dermal fillers, and noninvasive therapy, such as lasers, chemical peels, and microdermabrasion. However, treating age‐related ptosis in periorbital rejuvenation is mainly addressed surgically. The newly approved α‐adrenergic receptor agonist oxymetazoline hydrochloride ophthalmic solution, 0.1%, provides a novel non‐interventional approach to blepharoptosis.
Conclusions
Facial rejuvenation is highly sought‐after in this post‐pandemic era. Each nonsurgical treatment option has its advantages and drawbacks. A patient‐centered approach is necessary to select the appropriate procedure considering the patient's concerns and aesthetic sensibilities. The eyes are an area of primary concern for patients, yet surgery is the gold standard for treating ptosis. Oxymetazoline hydrochloride ophthalmic solution, 0.1%, is a safe and effective nonsurgical treatment for blepharoptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Schweiger Dermatology Group, Hackensack, New Jersey, USA.
- Icahn School of Medicine at Mt. Sinai, New York, New York, USA.
- Radboud UMC Nijmegen, Andriessen Consultants, Malden, The Netherlands.
- Gold Skin Care Center, Vanderbilt University School of Nursing, Nashville, Tennessee, USA.
- Department of Dermatology, NYU School of Medicine, New York, New York, USA.
- Cosmetic Enhancement Center for Clinical and Cosmetic Research, Aventura, Florida, USA.
ORCID-Profile: David J Goldberg, Anneke Andriessen, Michael Gold, Margarita S Lolis, Shari Marchbein
Förderung
- RVL Pharmaceuticals
Zitieren
APA
Goldberg, D. J., Andriessen, A., Gold, M., Lolis, M. S., Marchbein, S., Nestor, M. S., & Ros, A. (2024). A review of nonsurgical facial rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1% in periorbital revitalization. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16018
Vancouver
Goldberg DJ, Andriessen A, Gold M, Lolis MS, Marchbein S, Nestor MS, et al. A review of nonsurgical facial rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1% in periorbital revitalization. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16018
BibTeX
@article{Goldberg2024,
author = {Goldberg, David J and Andriessen, Anneke and Gold, Michael and Lolis, Margarita S and Marchbein, Shari and Nestor, Mark S and Ros, Adriana},
title = {A review of nonsurgical facial rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1% in periorbital revitalization},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
doi = {10.1111/jocd.16018}
}
EUVIMED